Rome, Nov 6. (Adnkronos Health) – Why does prostate cancer respond so limitedly to immunotherapy? The answer could lie in a molecular mechanism traceable through a simple blood test. This is revealed by a multidisciplinary study resulting from the collaboration between Link Campus University, the Institute of Translational Pharmacology (Cnr-Ift), Irccs Life Santa Lucia, Sapienza University of Rome, and Policlinico Umberto I of Rome. The research – a note informs – is published in the journal ‘Journal of Experimental & Clinical Cancer Research’.
“The tumor releases tiny bubbles into the bloodstream, extracellular vesicles, loaded with two specific microRNAs (miR-302a-5p and miR-367-3p) capable of switching off the activity of macrophages, the immune system cells that should attack cancer,” explains Giuseppina Catanzaro, associate professor at Link Campus University. “This process transforms the neoplasm into a cold tumor, meaning invisible and not attackable by the body’s defenses. Macrophages are ‘plastic’ cells that can adopt an aggressive attitude (M1 phenotype) or a tolerant and reparative one that promotes tumor growth (M2 phenotype). The study showed that in patients, circulating monocytes – the precursors of macrophages – give rise to macrophages already oriented towards the tolerant M2 state, and that this tendency increases with the aggressiveness of the disease”.
Analyzing the peripheral blood of nearly 80 patients undergoing examinations for suspected prostate cancer, researchers demonstrated that this “reprogramming” depends precisely on miR-302a-5p and miR-367-3p, whose elevated levels in macrophages correspond to a loss of inflammatory capacity and an increase in immune tolerance markers. Through the use of genetically advanced LNA (Locked Nucleic Acid) technology in the laboratory, the team succeeded in blocking these two molecules and reigniting the anti-tumor action of macrophages.
“Until today, it was thought that the prostate tumor microenvironment became ‘cold’ due to the exchange of proximity signals between tumor cells and immune cells – clarifies Catanzaro – Our research shows instead that immune ‘cooling’ begins much earlier, directly in the blood, where macrophage precursors are educated by vesicles released by the tumor. This occurs through a precise molecular code that can be identified with a simple blood test, opening up the possibility of identifying patients who can truly benefit from cellular reprogramming strategies, to be combined with current therapies”.
“The relevance of this discovery lies in the fact that this signal is not an indistinct shadow, but a concrete lever for action,” highlights Valerio Chiurchiù, senior researcher at the Institute of Translational Pharmacology (Cnr-Ift) and director of the Inflammation Resolution Laboratory at Irccs Life Santa Lucia in Rome. “By inhibiting two specific microRNAs – the expert continues – we brought the patients’ macrophages back towards the anti-tumor phenotype, a very encouraging sign of selectivity. We know that much remains to be done to translate this mechanism into a therapy – in vivo studies, safety tests, and the development of targeted drug delivery strategies are needed – but the fact that a tumor so resistant to immunotherapy retains a latent and reactivable inflammatory propensity changes the prospective scenario. This is a promising start, not the end”.
This work is the result of close collaboration between groups with diverse and complementary expertise. The multidisciplinary approach – the note concludes – has allowed for the integration of perspectives and knowledge from clinical practice, molecular biology, immunology, and bioinformatics, creating a synergistic dialogue between disciplines that has fostered a more complete and innovative vision in the fight against resistant oncological pathologies.